Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 15;1(2):100006.
doi: 10.1016/j.bneo.2024.100006. eCollection 2024 Jun.

Frequent response monitoring in chronic lymphocytic leukemia clinical trials: what is the value?

Agnes Mattsson  1   2 , Jeanette Lundin  1   3 , Tom A Mulder  1 , Sandra E Sylvan  1 , Marzia Palma  1   3 , Lotta Hansson  1   3 , Anders Österborg  1   3
Affiliations

Frequent response monitoring in chronic lymphocytic leukemia clinical trials: what is the value?

Agnes Mattsson et al. Blood Neoplasia. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: A.Ö. and M.P. have received unrestricted scientific grants from 10.13039/100017239BeiGene. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Time to Response and Time to Progression. (A) TTR according to clinical trial protocol or iwCLL Guidelines. (B) Time to progression according to clinical trial protocol or iwCLL guidelines.
See this image and copyright information in PMC

References

    1. Hallek M, Cherson BD, Catovsky D, et al. IwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. - PubMed
    1. Eichhorst BF, Fischer K, Fink AM, et al. Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. Blood. 2011;117(6):1817–1821. - PubMed
    1. Ghia P, Pluta A, Wach M, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849–2861. - PubMed
    1. O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409–1418. - PubMed
    1. Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomized, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031–1043. - PubMed

LinkOut - more resources